Keryx Biopharma (KERX) Posts Q4 Loss of 44c/Share

Keryx Biopharma (NASDAQ: KERX) reported Q4 EPS of ($0.44), $0.07 worse than the analyst estimate of ($0.37). Revenue for the quarter came in at $569 thousand versus the consensus estimate of $1.39 million.

At December 31, 2014, the Company had cash, cash equivalents, interest receivable and investment securities of $85.8 million, as compared to $55.7 million at December 31, 2013. Subsequent to December 31, 2014, the Company completed an underwritten public offering of common stock, which provided proceeds to the Company of approximately $118.3 million, net of underwriting discounts and offering expenses of approximately $8.2 million.

For earnings history and earnings-related data on Keryx Biopharma (KERX) click here.

You May Also Be Interested In

• Kinder Morgan (KMI) Misses Q1 EPS by 1c
• First Industrial Realty (FR) Tops Q1 EPS by 21c
• CSX Corp. (CSX) Tops Q1 EPS by 1c